Reports
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States
Americas
Future Market Insights, Inc.
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
MEA
Future Market Insights
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom
Asia Pacific
Future Market Insights
IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India
The global cancer tissue diagnostics market is expected to reach a market valuation of US$ 7,041 million by 2023, accelerating with a moderate CAGR of 6.5% from 2023 to 2033. The cancer tissue diagnostics market is anticipated to be valued at US$ 13,219 million by 2033 end.
The biological context of cancer cells may be captured by tissue diagnostics, making them one of the most reliable methods for making a cancer diagnosis and treatment plan. High demand and promising future growth in the cancer tissue diagnostics market might be attributed to the rising cancer rate.
Increased adoption of automated cancer diagnosis methods and technologies by research institutes facilitates quicker tumor diagnosis. The West Clinic Cancer Center, for instance, teamed with F. Hoffmann-La Roche Ltd. in September 2019 to use the BenchMark ULTRA Automated Advanced Staining System, developed by Roche, to enhance patient cancer treatment. In situ, hybridization and immunohistochemistry testing can be performed using this technology for quicker cancer tissue diagnostics.
Several factors, including the rising incidence of cancers of all kinds, the growing interest in preventative health care, the expansion of digital pathology's applications, the intensification of cancer awareness campaigns, the development of more effective diagnostic and monitoring tools, and the general improvement in diagnostic accuracy, bode well for the global cancer tissue diagnostics industry.
While the global cancer tissue diagnostics industry is expected to expand during the forecast period, its expansion is expected to be hindered by factors such as the high price of diagnostic procedures and a lack of experienced and professional workers.
Attributes | Value |
---|---|
Cancer Tissue Diagnostics Market Size (2023) | US$ 7,041 million |
Cancer Tissue Diagnostics Market Projected Size (2033) | US$ 13,219 million |
Cancer Tissue Diagnostics Market Value CAGR (2023 to 2033) | 6.5% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Cancer Diagnostics Research to Drive the Market Demand
The rise in cancer incidence has boosted cancer tissue diagnostics research and development. According to the WHO, the global cancer burden grew in 2020, with 18 million new cases and 9.6 million deaths (WHO). Increased academic-commercial partnerships to further cancer research are likely to increase the global cancer tissue diagnostics industry.
The University of Sheffield in the United Kingdom signed a collaboration agreement with Zilico Ltd in June 2020 to develop a painless, fast, and non-invasive oral cancer diagnosis using EIS technology.
Swiss life-sciences firm Lunaphore Technologies SA develops next-generation cancer research equipment. In the same month, Epredia, a global leader in cancer and tissue diagnostics, signed a strategic distribution deal with the firm. Fast Fluidic Exchange microfluidic technology is forecast to be integrated into tissue diagnostic instruments by industry leader Lunaphore to deliver chemicals to tissue samples for quick IHC and immunofluorescence assays (IF).
Histology laboratories are vital to the accuracy, safety, and speed of sickness diagnosis. Histology is needed to understand illness causes and how therapies operate. Cancer rates increase the requirement for clinical histology services. 80% of cancer diagnostics involve histology. These facilities are understaffed.
According to Inside Lab 2020, only 3% of United Kingdom diagnostic labs had enough staff to perform diagnostic and regular tasks, including reporting. Germany has the lowest proportion of pathologists to practicing physicians in Europe, the United States, and Canada. Germany's ratio is 1:200, while the United States and Canada have 1:70. PubMed 2020 As many histologists retire, few are entering the field. Histology labs are struggling to process more samples with fewer workers. This could limit the cancer tissue diagnostics industry's growth.
Cancer remains one of the world's deadliest diseases despite significant progress in cancer treatment and detection over the previous several decades. The finest weapons doctors have against this disease are identification and treatment administered early on. However, difficulties, such as high false-positive rates and difficulty forecasting cancer treatment success, can impede the process.
Now, healthcare experts and medical researchers are discovering methods to use the latest advancements from outside of medicine - like artificial intelligence - to diagnose and treat cancer. Here are just three examples of such cutting-edge equipment.
Immunotherapy is a novel approach to cancer treatment that makes use of medications to stimulate the immune system to combat cancer cells better. Compared to conventional therapies like chemotherapy and radiation, this often has fewer negative side effects and better success rates. Yet not every patient has the same experience, and the efficacy of immunotherapy cannot be predicted.
This could potentially alter with the introduction of a new artificial intelligence technology. Patients likely to benefit from immunotherapy could be selected using an algorithm with routine CT scans. This may expedite their cancer treatment while also allowing doctors to treat other patients who are waiting for alternatives like chemotherapy.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The use of mass spectrometry for imaging purposes is a significant technological advance in spectral research. A 3D chemical map can be created by examining the spectra of individual molecules in tissue. This method has many potential applications, including the detection of hypoxic tumor sites, the characterization of spheroids, and the evaluation of alterations in the tumor microenvironment (TME). Recent technological advancements have made it possible to take these measurements at high throughput, casting doubt on the feasibility of routine 3D tumor investigations.
Improvements in dependability and data management are largely responsible for the growth of next-generation sequencing in the therapeutic setting. The past decade has seen NGS facilitate the discovery of novel genomic variants and driving mutations, clarifying new targets for medication development. Thanks to NGS, researchers have also been able to pinpoint more accurate predictive and prognostic biomarkers for therapy.
Genomics England launched the 100,000 Genomes Initiative in 2012, making it a leading sequencing research project in the world to promote improved diagnosis and cancer treatment decisions. The research is also expected to improve 'genome-friendly' tissue processing techniques.
Cancer Tissue Diagnostics Market:
Attributes | Cancer Tissue Diagnostics Market |
---|---|
CAGR (2023 to 2033) | 6.5% |
Market Value (2023) | US$ 7,041 million |
Growth Factor | An increase in cases of cancer is expected to drive the cancer tissue diagnostics industry. |
Future Opportunities | The increased emphasis on individualized medical cancer treatment is opening new horizons in the cancer tissue diagnostics industry. |
Market Trends | The lack of available and skilled workers is expected to retrain the growth of the cancer tissue diagnostics industry. |
Molecular Diagnostics Market:
Attributes | Molecular Diagnostics Market |
---|---|
CAGR (2023 to 2033) | 5.4% |
Market Value (2023) | US$ 24.45 billion |
Growth Factor | Both increasing technological capabilities in molecular diagnostics and rising awareness of the importance of early disease diagnosis in developing countries are propelling the market forward. |
Future Opportunities | Market leaders in molecular diagnostics can anticipate expanding prospects in developing economies, including India, China, South Korea, Brazil, Turkey, Russia, and South Africa. |
Market Trends | A crucial barrier limiting the expansion of the molecular diagnostics business is inadequate reimbursements. |
In-vitro Diagnostics Market:
Attributes | In-vitro Diagnostics Market |
---|---|
CAGR (2023 to 2033) | 2.9% |
Market Value (2023) | US$ 101.05 billion |
Growth Factor | The need is anticipated to be driven by the transition from centralized to point-of-care testing. |
Future Opportunities | Growth possibilities for market players are anticipated to emerge from developing disease-specific markers and diagnostics in the future years. |
Market Trends | The in vitro diagnostics market is likely to slow down in the coming years due to the adverse reimbursement scenario. |
The rising cancer cell rate has resulted in a surge in interest in oncology diagnostics. This has prompted government agencies, healthcare providers, and institutions to create facilities for effective illness diagnosis and treatment. Because of this, the cancer tissue diagnostics industry is growing rapidly. Roche's uPath HER2 (4B5) and uPath HER2 Dual ISH digital pathology image analyzers are algorithms for the precise patient diagnosis of breast cancer, and they were released in 2021. This is positively changing the cancer tissue diagnostics market outlook.
Attributes | Details |
---|---|
The United States Value Share % (2022) | 32.6% |
Germany Value Share % (2022) | 4.5% |
Japan Value Share % (2022) | 5.2% |
Australia’s Growth Rate (2023 to 2033) | 10.3% |
China’s Growth Rate (2023 to 2033) | 7.5% |
India’s Growth Rate (2023 to 2033) | 6.4% |
The United Kingdom’s Growth Rate (2023 to 2033) | 4.9% |
Attributes | Details |
---|---|
United States |
|
Japan |
|
China |
|
Germany |
|
Top companies in the cancer tissue diagnostics industry are paying more attention to the growing demand for their products in digital pathology. This is expected to prompt strategic partnerships in the global cancer tissue diagnostics industry between technology providers and digital pathology platforms soon.
In July 2020, for instance, Koninklijke Philips N.V., a Dutch multinational conglomerate corporation and one of the world's leading electronics companies with a focus on health technology, announced that it had partnered with Proscia Inc., a Philadelphia-based provider of digital pathology platform, to establish an open ecosystem for diagnostic laboratories to boost and scale their operations on the platform of digital pathologies.
Through this partnership, Philips' iSyntax image format is expected to be integrated with the Philips Pathology SDK software toolset, and Proscia's suite of AI modules can be made available on the company's Concentric digital pathology platform.
The Swiss pharmaceutical and diagnostics conglomerate F. Hoffmann-La Roche AG announced the CE-IVD launch of its cutting-edge, fully automated digital pathology platform uPath PD-L1 (SP263) for non-small cell lung cancer research in June 2020. (NSCLC).
The firm stated that the decision was motivated by a desire to increase reliability and uniformity in diagnostic laboratories by implementing AI-powered image analysis capabilities.
The market is valued at US$ 7,041 million in 2023.
The global cancer tissue diagnostics market size is anticipated to surpass US$ 13,219 million by 2033.
The cancer tissue diagnostics market is projected to accelerate at a CAGR of 6.5% between 2023 and 2033.
The United States holds substantial prospects for cancer tissue diagnostics with a 32.6% share.
Key cancer tissue diagnostics market players are Abbott Laboratories, Thermo Fisher Scientific Inc., and Ventana Medical Systems.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Test Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Test Type, 2023 to 2033 5.3.1. Immunohistochemical (IHC) Test 5.3.1.1. Breast Cancer 5.3.1.2. Stomach (Gastric) Cancer 5.3.1.3. Colorectal Cancer 5.3.1.4. Prostate Cancer 5.3.1.5. Others 5.3.2. In Situ Hybridization (ISH) Test 5.3.2.1. Breast cancer 5.3.2.2. Non-Small Cell Lung Cancer (NSCLC) 5.3.2.3. Bladder Cance 5.3.2.4. Others 5.4. Y-o-Y Growth Trend Analysis By Test Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Test Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 6.1. Introduction 6.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 6.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 6.3.1. North America 6.3.2. Latin America 6.3.3. Western Europe 6.3.4. Eastern Europe 6.3.5. South Asia and Pacific 6.3.6. East Asia 6.3.7. Middle East and Africa 6.4. Market Attractiveness Analysis By Region 7. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 7.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 7.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 7.2.1. By Country 7.2.1.1. USA 7.2.1.2. Canada 7.2.2. By Test Type 7.3. Market Attractiveness Analysis 7.3.1. By Country 7.3.2. By Test Type 7.4. Key Takeaways 8. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 8.2.1. By Country 8.2.1.1. Brazil 8.2.1.2. Mexico 8.2.1.3. Rest of Latin America 8.2.2. By Test Type 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Test Type 8.4. Key Takeaways 9. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. Germany 9.2.1.2. UK 9.2.1.3. France 9.2.1.4. Spain 9.2.1.5. Italy 9.2.1.6. Rest of Western Europe 9.2.2. By Test Type 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Test Type 9.4. Key Takeaways 10. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Poland 10.2.1.2. Russia 10.2.1.3. Czech Republic 10.2.1.4. Romania 10.2.1.5. Rest of Eastern Europe 10.2.2. By Test Type 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Test Type 10.4. Key Takeaways 11. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. India 11.2.1.2. Bangladesh 11.2.1.3. Australia 11.2.1.4. New Zealand 11.2.1.5. Rest of South Asia and Pacific 11.2.2. By Test Type 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Test Type 11.4. Key Takeaways 12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.2. By Test Type 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Test Type 12.4. Key Takeaways 13. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. GCC Countries 13.2.1.2. South Africa 13.2.1.3. Israel 13.2.1.4. Rest of MEA 13.2.2. By Test Type 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Test Type 13.4. Key Takeaways 14. Key Countries Market Analysis 14.1. USA 14.1.1. Pricing Analysis 14.1.2. Market Share Analysis, 2022 14.1.2.1. By Test Type 14.2. Canada 14.2.1. Pricing Analysis 14.2.2. Market Share Analysis, 2022 14.2.2.1. By Test Type 14.3. Brazil 14.3.1. Pricing Analysis 14.3.2. Market Share Analysis, 2022 14.3.2.1. By Test Type 14.4. Mexico 14.4.1. Pricing Analysis 14.4.2. Market Share Analysis, 2022 14.4.2.1. By Test Type 14.5. Germany 14.5.1. Pricing Analysis 14.5.2. Market Share Analysis, 2022 14.5.2.1. By Test Type 14.6. UK 14.6.1. Pricing Analysis 14.6.2. Market Share Analysis, 2022 14.6.2.1. By Test Type 14.7. France 14.7.1. Pricing Analysis 14.7.2. Market Share Analysis, 2022 14.7.2.1. By Test Type 14.8. Spain 14.8.1. Pricing Analysis 14.8.2. Market Share Analysis, 2022 14.8.2.1. By Test Type 14.9. Italy 14.9.1. Pricing Analysis 14.9.2. Market Share Analysis, 2022 14.9.2.1. By Test Type 14.10. Poland 14.10.1. Pricing Analysis 14.10.2. Market Share Analysis, 2022 14.10.2.1. By Test Type 14.11. Russia 14.11.1. Pricing Analysis 14.11.2. Market Share Analysis, 2022 14.11.2.1. By Test Type 14.12. Czech Republic 14.12.1. Pricing Analysis 14.12.2. Market Share Analysis, 2022 14.12.2.1. By Test Type 14.13. Romania 14.13.1. Pricing Analysis 14.13.2. Market Share Analysis, 2022 14.13.2.1. By Test Type 14.14. India 14.14.1. Pricing Analysis 14.14.2. Market Share Analysis, 2022 14.14.2.1. By Test Type 14.15. Bangladesh 14.15.1. Pricing Analysis 14.15.2. Market Share Analysis, 2022 14.15.2.1. By Test Type 14.16. Australia 14.16.1. Pricing Analysis 14.16.2. Market Share Analysis, 2022 14.16.2.1. By Test Type 14.17. New Zealand 14.17.1. Pricing Analysis 14.17.2. Market Share Analysis, 2022 14.17.2.1. By Test Type 14.18. China 14.18.1. Pricing Analysis 14.18.2. Market Share Analysis, 2022 14.18.2.1. By Test Type 14.19. Japan 14.19.1. Pricing Analysis 14.19.2. Market Share Analysis, 2022 14.19.2.1. By Test Type 14.20. South Korea 14.20.1. Pricing Analysis 14.20.2. Market Share Analysis, 2022 14.20.2.1. By Test Type 14.21. GCC Countries 14.21.1. Pricing Analysis 14.21.2. Market Share Analysis, 2022 14.21.2.1. By Test Type 14.22. South Africa 14.22.1. Pricing Analysis 14.22.2. Market Share Analysis, 2022 14.22.2.1. By Test Type 14.23. Israel 14.23.1. Pricing Analysis 14.23.2. Market Share Analysis, 2022 14.23.2.1. By Test Type 15. Market Structure Analysis 15.1. Competition Dashboard 15.2. Competition Benchmarking 15.3. Market Share Analysis of Top Players 15.3.1. By Regional 15.3.2. By Test Type 16. Competition Analysis 16.1. Competition Deep Dive 16.1.1. Abbott Laboratories 16.1.1.1. Overview 16.1.1.2. Product Portfolio 16.1.1.3. Profitability by Market Segments 16.1.1.4. Sales Footprint 16.1.1.5. Strategy Overview 16.1.1.5.1. Marketing Strategy 16.1.2. F.Hoffmann-La Roche Ltd. 16.1.2.1. Overview 16.1.2.2. Product Portfolio 16.1.2.3. Profitability by Market Segments 16.1.2.4. Sales Footprint 16.1.2.5. Strategy Overview 16.1.2.5.1. Marketing Strategy 16.1.3. Thermo Fisher Scientific Inc. 16.1.3.1. Overview 16.1.3.2. Product Portfolio 16.1.3.3. Profitability by Market Segments 16.1.3.4. Sales Footprint 16.1.3.5. Strategy Overview 16.1.3.5.1. Marketing Strategy 16.1.4. Ventana Medical Systems, Inc. 16.1.4.1. Overview 16.1.4.2. Product Portfolio 16.1.4.3. Profitability by Market Segments 16.1.4.4. Sales Footprint 16.1.4.5. Strategy Overview 16.1.4.5.1. Marketing Strategy 16.1.5. Bio Rad Laboratories Inc. 16.1.5.1. Overview 16.1.5.2. Product Portfolio 16.1.5.3. Profitability by Market Segments 16.1.5.4. Sales Footprint 16.1.5.5. Strategy Overview 16.1.5.5.1. Marketing Strategy 16.1.6. Enzo Life Sciences, Inc. 16.1.6.1. Overview 16.1.6.2. Product Portfolio 16.1.6.3. Profitability by Market Segments 16.1.6.4. Sales Footprint 16.1.6.5. Strategy Overview 16.1.6.5.1. Marketing Strategy 16.1.7. Abcam plc 16.1.7.1. Overview 16.1.7.2. Product Portfolio 16.1.7.3. Profitability by Market Segments 16.1.7.4. Sales Footprint 16.1.7.5. Strategy Overview 16.1.7.5.1. Marketing Strategy 16.1.8. BioGenex 16.1.8.1. Overview 16.1.8.2. Product Portfolio 16.1.8.3. Profitability by Market Segments 16.1.8.4. Sales Footprint 16.1.8.5. Strategy Overview 16.1.8.5.1. Marketing Strategy 16.1.9. Cell Signalling Technology, Inc. 16.1.9.1. Overview 16.1.9.2. Product Portfolio 16.1.9.3. Profitability by Market Segments 16.1.9.4. Sales Footprint 16.1.9.5. Strategy Overview 16.1.9.5.1. Marketing Strategy 16.1.10. Agilent Technologies, Inc. 16.1.10.1. Overview 16.1.10.2. Product Portfolio 16.1.10.3. Profitability by Market Segments 16.1.10.4. Sales Footprint 16.1.10.5. Strategy Overview 16.1.10.5.1. Marketing Strategy 17. Assumptions & Acronyms Used 18. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033 Table 2: Global Market Value (US$ Million) Forecast by Test Type, 2018 to 2033 Table 3: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 4: North America Market Value (US$ Million) Forecast by Test Type, 2018 to 2033 Table 5: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 6: Latin America Market Value (US$ Million) Forecast by Test Type, 2018 to 2033 Table 7: Western Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 8: Western Europe Market Value (US$ Million) Forecast by Test Type, 2018 to 2033 Table 9: Eastern Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 10: Eastern Europe Market Value (US$ Million) Forecast by Test Type, 2018 to 2033 Table 11: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 12: South Asia and Pacific Market Value (US$ Million) Forecast by Test Type, 2018 to 2033 Table 13: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 14: East Asia Market Value (US$ Million) Forecast by Test Type, 2018 to 2033 Table 15: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 16: Middle East and Africa Market Value (US$ Million) Forecast by Test Type, 2018 to 2033
Figure 1: Global Market Value (US$ Million) by Test Type, 2023 to 2033 Figure 2: Global Market Value (US$ Million) by Region, 2023 to 2033 Figure 3: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033 Figure 4: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 5: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 6: Global Market Value (US$ Million) Analysis by Test Type, 2018 to 2033 Figure 7: Global Market Value Share (%) and BPS Analysis by Test Type, 2023 to 2033 Figure 8: Global Market Y-o-Y Growth (%) Projections by Test Type, 2023 to 2033 Figure 9: Global Market Attractiveness by Test Type, 2023 to 2033 Figure 10: Global Market Attractiveness by Region, 2023 to 2033 Figure 11: North America Market Value (US$ Million) by Test Type, 2023 to 2033 Figure 12: North America Market Value (US$ Million) by Country, 2023 to 2033 Figure 13: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 14: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 15: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 16: North America Market Value (US$ Million) Analysis by Test Type, 2018 to 2033 Figure 17: North America Market Value Share (%) and BPS Analysis by Test Type, 2023 to 2033 Figure 18: North America Market Y-o-Y Growth (%) Projections by Test Type, 2023 to 2033 Figure 19: North America Market Attractiveness by Test Type, 2023 to 2033 Figure 20: North America Market Attractiveness by Country, 2023 to 2033 Figure 21: Latin America Market Value (US$ Million) by Test Type, 2023 to 2033 Figure 22: Latin America Market Value (US$ Million) by Country, 2023 to 2033 Figure 23: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 24: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 25: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 26: Latin America Market Value (US$ Million) Analysis by Test Type, 2018 to 2033 Figure 27: Latin America Market Value Share (%) and BPS Analysis by Test Type, 2023 to 2033 Figure 28: Latin America Market Y-o-Y Growth (%) Projections by Test Type, 2023 to 2033 Figure 29: Latin America Market Attractiveness by Test Type, 2023 to 2033 Figure 30: Latin America Market Attractiveness by Country, 2023 to 2033 Figure 31: Western Europe Market Value (US$ Million) by Test Type, 2023 to 2033 Figure 32: Western Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 33: Western Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 34: Western Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 35: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 36: Western Europe Market Value (US$ Million) Analysis by Test Type, 2018 to 2033 Figure 37: Western Europe Market Value Share (%) and BPS Analysis by Test Type, 2023 to 2033 Figure 38: Western Europe Market Y-o-Y Growth (%) Projections by Test Type, 2023 to 2033 Figure 39: Western Europe Market Attractiveness by Test Type, 2023 to 2033 Figure 40: Western Europe Market Attractiveness by Country, 2023 to 2033 Figure 41: Eastern Europe Market Value (US$ Million) by Test Type, 2023 to 2033 Figure 42: Eastern Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 43: Eastern Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 44: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 45: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 46: Eastern Europe Market Value (US$ Million) Analysis by Test Type, 2018 to 2033 Figure 47: Eastern Europe Market Value Share (%) and BPS Analysis by Test Type, 2023 to 2033 Figure 48: Eastern Europe Market Y-o-Y Growth (%) Projections by Test Type, 2023 to 2033 Figure 49: Eastern Europe Market Attractiveness by Test Type, 2023 to 2033 Figure 50: Eastern Europe Market Attractiveness by Country, 2023 to 2033 Figure 51: South Asia and Pacific Market Value (US$ Million) by Test Type, 2023 to 2033 Figure 52: South Asia and Pacific Market Value (US$ Million) by Country, 2023 to 2033 Figure 53: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 54: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 55: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 56: South Asia and Pacific Market Value (US$ Million) Analysis by Test Type, 2018 to 2033 Figure 57: South Asia and Pacific Market Value Share (%) and BPS Analysis by Test Type, 2023 to 2033 Figure 58: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Test Type, 2023 to 2033 Figure 59: South Asia and Pacific Market Attractiveness by Test Type, 2023 to 2033 Figure 60: South Asia and Pacific Market Attractiveness by Country, 2023 to 2033 Figure 61: East Asia Market Value (US$ Million) by Test Type, 2023 to 2033 Figure 62: East Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 63: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 64: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 65: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 66: East Asia Market Value (US$ Million) Analysis by Test Type, 2018 to 2033 Figure 67: East Asia Market Value Share (%) and BPS Analysis by Test Type, 2023 to 2033 Figure 68: East Asia Market Y-o-Y Growth (%) Projections by Test Type, 2023 to 2033 Figure 69: East Asia Market Attractiveness by Test Type, 2023 to 2033 Figure 70: East Asia Market Attractiveness by Country, 2023 to 2033 Figure 71: Middle East and Africa Market Value (US$ Million) by Test Type, 2023 to 2033 Figure 72: Middle East and Africa Market Value (US$ Million) by Country, 2023 to 2033 Figure 73: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 74: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 75: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 76: Middle East and Africa Market Value (US$ Million) Analysis by Test Type, 2018 to 2033 Figure 77: Middle East and Africa Market Value Share (%) and BPS Analysis by Test Type, 2023 to 2033 Figure 78: Middle East and Africa Market Y-o-Y Growth (%) Projections by Test Type, 2023 to 2033 Figure 79: Middle East and Africa Market Attractiveness by Test Type, 2023 to 2033 Figure 80: Middle East and Africa Market Attractiveness by Country, 2023 to 2033
Recommendations
Explore Healthcare Insights
View Reports